Characterization And Impurity Profiling Of Combined Amylin And GLP-1 Analogs With RapiZyme Trypsin

By Caitlin M. Hanna, Stephan M. Koza, and Steve Shiner, Waters Corporation

Glucagon-like peptide 1 receptor agonists (GLP-1RAs) are a rapidly growing class of biotherapeutic peptide-like drugs, increasingly used for managing Type 2 diabetes and promoting weight loss. These therapeutics are often modified with fatty acids to enhance their potency, which introduces complexity in reversed-phase (RP) impurity analysis. To further improve treatment outcomes, researchers are developing combined lipopeptide therapeutics that target multiple receptors simultaneously. One such example involves the combination of amylin and GLP-1 analogs, specifically cagrilintide and semaglutide. For the detailed characterization and impurity profiling of these combined therapeutics, Waters™ RapiZyme™ Trypsin proves to be a powerful tool. It enables a comprehensive bottom-up analysis with over 99.5% digestion completion, facilitating the identification of peptide residue modifications and ensuring high-quality therapeutic development.

Explore how RapiZyme Trypsin can streamline your peptide analysis workflows and elevate your biotherapeutic research.